Y-mAbs Therapeutics (YMAB) Competitors $8.51 -0.02 (-0.18%) As of 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock YMAB vs. CRMD, IMTX, OCS, NUVB, QURE, PHAR, CRON, SION, ANAB, and GHRSShould you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include CorMedix (CRMD), Immatics (IMTX), Oculis (OCS), Nuvation Bio (NUVB), uniQure (QURE), Pharming Group (PHAR), Cronos Group (CRON), Sionna Therapeutics (SION), AnaptysBio (ANAB), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry. Y-mAbs Therapeutics vs. Its Competitors CorMedix Immatics Oculis Nuvation Bio uniQure Pharming Group Cronos Group Sionna Therapeutics AnaptysBio GH Research CorMedix (NASDAQ:CRMD) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment. Does the media prefer CRMD or YMAB? In the previous week, Y-mAbs Therapeutics had 12 more articles in the media than CorMedix. MarketBeat recorded 14 mentions for Y-mAbs Therapeutics and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.04 beat Y-mAbs Therapeutics' score of 0.31 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Y-mAbs Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in CRMD or YMAB? 34.2% of CorMedix shares are held by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are held by institutional investors. 5.3% of CorMedix shares are held by insiders. Comparatively, 19.7% of Y-mAbs Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is CRMD or YMAB more profitable? CorMedix has a net margin of 20.81% compared to Y-mAbs Therapeutics' net margin of -31.84%. CorMedix's return on equity of 22.57% beat Y-mAbs Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CorMedix20.81% 22.57% 17.02% Y-mAbs Therapeutics -31.84%-30.59%-22.70% Which has better earnings & valuation, CRMD or YMAB? CorMedix has higher earnings, but lower revenue than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M18.62-$17.93M$0.2254.25Y-mAbs Therapeutics$87.68M4.39-$29.67M-$0.64-13.29 Do analysts recommend CRMD or YMAB? CorMedix currently has a consensus price target of $17.14, suggesting a potential upside of 43.64%. Y-mAbs Therapeutics has a consensus price target of $11.16, suggesting a potential upside of 31.22%. Given CorMedix's stronger consensus rating and higher possible upside, equities research analysts clearly believe CorMedix is more favorable than Y-mAbs Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Y-mAbs Therapeutics 2 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.33 Which has more risk and volatility, CRMD or YMAB? CorMedix has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. SummaryCorMedix beats Y-mAbs Therapeutics on 12 of the 17 factors compared between the two stocks. Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart YMAB vs. The Competition Export to ExcelMetricY-mAbs TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$385.11M$2.97B$5.48B$9.54BDividend YieldN/A2.41%4.71%4.14%P/E Ratio-13.2917.1428.7323.79Price / Sales4.39306.13439.6695.98Price / CashN/A42.6035.6858.35Price / Book4.157.988.155.60Net Income-$29.67M-$54.52M$3.25B$265.17M7 Day Performance77.56%-1.08%-0.99%-0.94%1 Month Performance97.56%13.37%5.25%4.95%1 Year Performance-23.52%11.25%28.32%23.30% Y-mAbs Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)YMABY-mAbs Therapeutics2.6708 of 5 stars$8.51-0.2%$11.16+31.2%-20.8%$385.11M$87.68M-13.29150Trending NewsUpcoming EarningsAnalyst ForecastHigh Trading VolumeCRMDCorMedix2.5742 of 5 stars$12.37+6.3%$17.14+38.6%+197.0%$789.48M$43.47M56.2330News CoveragePositive NewsUpcoming EarningsIMTXImmatics2.197 of 5 stars$6.61+2.0%$14.67+121.9%-41.4%$787.65M$168.65M-38.88260News CoverageUpcoming EarningsOCSOculis3.0405 of 5 stars$17.94+1.4%$35.33+97.0%+53.3%$772.83M$780K-6.802Positive NewsNUVBNuvation Bio2.0304 of 5 stars$2.31+3.6%$7.17+210.2%-25.4%$758.79M$7.87M-0.9860Upcoming EarningsQUREuniQure2.4546 of 5 stars$13.77+0.6%$36.55+165.4%+84.7%$751.40M$27.12M-3.51500PHARPharming Group3.0133 of 5 stars$12.25+11.8%$30.00+144.9%+61.6%$750.92M$297.20M-94.23280Earnings ReportGap DownHigh Trading VolumeCRONCronos Group2.4114 of 5 stars$2.02+3.6%N/A-5.9%$748.42M$117.61M15.54450Upcoming EarningsSIONSionna TherapeuticsN/A$17.12+1.2%$38.50+124.9%N/A$746.59MN/A0.0035Lockup ExpirationANABAnaptysBio2.3147 of 5 stars$24.23-1.9%$47.13+94.5%-26.8%$725.40M$91.28M-5.00100Positive NewsGHRSGH Research2.2694 of 5 stars$13.44-2.2%$32.00+138.1%+14.1%$714.87MN/A-17.0110Positive News Related Companies and Tools Related Companies CRMD Competitors IMTX Competitors OCS Competitors NUVB Competitors QURE Competitors PHAR Competitors CRON Competitors SION Competitors ANAB Competitors GHRS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:YMAB) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free YMAB Stock Alerts